enzalutamideRecent, repeatedEvidence- NCT07908524 · Merck & Co., Inc · Phase 2 · live · background · “Enzalutamide” · registered Oct 2026
- NCT07871110 · TransThera Sciences (Nanjing), Inc. · Phase 2 · live · comparator · “Enzalutamide 160mg daily (oral)” · registered Oct 2026
- NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Enzalutamide” · registered Aug 2026
- NCT07711002 · AstraZeneca · Phase 3 · live · background · “Enzalutamide” · registered Jul 2026
- NCT07723248 · ORIC Pharmaceuticals · Phase 3 · live · comparator · “Enzalutamide” · registered Jun 2026
| Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized | 2131 studies | 2032 studies | comparator 18 · background 30 |
Abiraterone AcetateRecent, repeatedEvidence- NCT07908524 · Merck & Co., Inc · Phase 2 · live · background · “Abiraterone acetate” · registered Oct 2026
- NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Abiraterone” · registered Aug 2026
- NCT07711002 · AstraZeneca · Phase 3 · live · background · “Abiraterone” · registered Jul 2026
- NCT07641855 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Abiraterone” · registered Jun 2026
- NCT07620574 · Exelixis · Phase 3 · live · background · “Abiraterone” · registered May 2026
| Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized | 1829 studies | 1634 studies | comparator 15 · background 36 |
DocetaxelRecent, repeatedEvidence- NCT07908524 · Merck & Co., Inc · Phase 2 · live · comparator · “Docetaxel” · registered Oct 2026
- NCT07723248 · ORIC Pharmaceuticals · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
- NCT07632690 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
- NCT07590934 · AstraZeneca · Phase 2 · live · comparator · “Docetaxel” · registered May 2026
- NCT07365995 · BioNTech SE · Phase 3 · live · comparator · “Docetaxel” · registered Jan 2026
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 1113 studies | 1215 studies | comparator 17 · background 24 |
PrednisoneRecent, repeatedPhase 4 trial recordedEvidence- NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Prednisone” · registered Aug 2026
- NCT07620574 · Exelixis · Phase 3 · live · background · “Prednisone” · registered May 2026
- NCT07365995 · BioNTech SE · Phase 3 · live · comparator · “Prednisone/prednisolone” · registered Jan 2026
- NCT06952803 · AstraZeneca · Phase 3 · live · background · “Abiraterone + Prednisolone/Prednisone” · registered Apr 2025
- NCT06925737 · Merck & Co., Inc · Phase 3 · live · comparator · “Prednisone” · registered Apr 2025
| Johnson & Johnson11% of its industry studies | 68 studies | 814 studies | background 66 · comparator 8 |
PrednisoloneRecent, repeatedPhase 4 trial recordedEvidence- NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Prednisolone” · registered Aug 2026
- NCT07553988 · R-Pharm · Phase 2 · live · comparator · “Prednisolone” · registered Apr 2026
- NCT07365995 · BioNTech SE · Phase 3 · live · comparator · “Prednisone/prednisolone” · registered Jan 2026
- NCT06952803 · AstraZeneca · Phase 3 · live · background · “Abiraterone + Prednisolone/Prednisone” · registered Apr 2025
- NCT05288166 · Eli Lilly and Company · Phase 3 · live · background · “Prednisone or Prednisolone” · registered Mar 2022
| Sanofi15% of its industry studies | 55 studies | 55 studies | comparator 3 · background 14 |
apalutamideRecent, repeatedEvidence- NCT07745361 · Monte Rosa Therapeutics, Inc · Phase 2 · live · background · “Apalutamide” · registered Jul 2026
- NCT07611110 · AstraZeneca · Phase 3 · live · background · “Apalutamide” · registered Apr 2026
- NCT05422911 · Sun Pharmaceutical Industries Limited · Phase 2 · live · comparator · “Apalutamide” · registered Jun 2022
| Johnson & Johnson87% of its industry studiesUS: Johnson & Johnson (FDA 2018)EU: Johnson & Johnson (EMA 2019) | 33 studies | 33 studies | background 2 · comparator 1 |
Antiandrogen TherapyRecent, repeatedEvidence- NCT07553988 · R-Pharm · Phase 2 · live · background · “Androgen deprivation therapy (ADT)” · registered Apr 2026
- NCT06952803 · AstraZeneca · Phase 3 · live · background · “Androgen Deprivation Therapy (ADT)” · registered Apr 2025
- NCT04108208 · Johnson & Johnson · Phase 4 · background · “Androgen-deprivation Therapy (ADT)” · registered Sep 2019
- NCT03767244 · Johnson & Johnson · Phase 3 · live · background · “Androgen Deprivation Therapy (ADT)” · registered Dec 2018
- NCT03641560 · Astellas Pharma Inc · Phase 4 · background · “Androgen deprivation therapy (ADT)” · registered Aug 2018
| — | 22 studies | 34 studies | background 8 |
cabazitaxelRecent, repeatedEvidence- NCT07611110 · AstraZeneca · Phase 3 · live · background · “Cabazitaxel” · registered Apr 2026
- NCT07213674 · Amgen · Phase 3 · live · comparator · “Cabazitaxel” · registered Sep 2025
- NCT06691984 · Amgen · Phase 3 · live · comparator · “Cabazitaxel” · registered Nov 2024
- NCT04495179 · AstraZeneca · Phase 2 · background · “Cabazitaxel” · registered Jul 2020
- NCT01578655 · Achieve Life Sciences · Phase 3 · background · “cabazitaxel” · registered Apr 2012
| Sanofi90% of its industry studiesEU: off-patent, 1 generic authorized | 23 studies | 23 studies | comparator 2 · background 4 |
atezolizumabRecent, repeatedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
- NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Atezolizumab” · registered Jan 2022
- NCT04471727 · Merck & Co., Inc · Phase 2 · live · background · “Atezolizumab” · registered Jul 2020
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 22 studies | 22 studies | background 3 |
darolutamideRecent, repeatedEvidence- NCT07871110 · TransThera Sciences (Nanjing), Inc. · Phase 2 · live · comparator · “Darolutamide 600 mg twice daily” · registered Oct 2026
- NCT07711002 · AstraZeneca · Phase 3 · live · background · “Darolutamide” · registered Jul 2026
- NCT07611110 · AstraZeneca · Phase 3 · live · background · “Darolutamide” · registered Apr 2026
- NCT06120491 · AstraZeneca · Phase 3 · live · background · “Darolutamide” · registered Oct 2023
| Bayer62% of its industry studiesUS: Bayer (FDA 2019)EU: Bayer (EMA 2020) | 24 studies | 24 studies | background 3 · comparator 1 |
olaparibRecent, repeatedEvidence- NCT07641855 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Olaparib” · registered Jun 2026
- NCT06065059 · Tango Therapeutics, Inc. · Phase 2 · background · “Olaparib” · registered Sep 2023
- NCT04556617 · Opna Bio LLC · Phase 2 · background · “Olaparib” · registered Sep 2020
| AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014) | 22 studies | 11 study | background 3 |
prednisone acetateRecent, repeatedPhase 4 trial recordedEvidence- NCT06136650 · Merck & Co., Inc · Phase 3 · live · comparator · “Prednisone acetate” · registered Nov 2023
- NCT05405439 · Sino Biopharmaceutical Limited · Phase 2 · background · “prednisone acetate tablets” · registered May 2022
| Jiangsu HengRui Medicine Co., Ltd.50% of its industry studies | 22 studies | 11 study | comparator 1 · background 1 |